Akt/cAMP-responsive element binding protein/cyclin D1 network: A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract

Clinical Cancer Research

Volumn 13, Issue 9, 2007, Pages 2784-2794

  Kumar, Addanki P ^a   Bhaskaran, Shylesh ^a   Ganapathy, Manonmani ^a   Crosby, Katherine ^c   Davis, Michael D ^b   Kochunov, Peter ^b   Schoolfield, John ^b   Yeh, I Tien ^a   Troyer, Dean A ^a   Ghosh, Rita ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CAMO RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; NEXRUTINE; PHELLONDENDRON AMURENSE EXTRACT; PLANT EXTRACT; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; CORK TREE; DRUG EFFICACY; DRUG INHIBITION; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN PHOSPHORYLATION; RUTACEAE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CELL PROLIFERATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN D1; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25;

EID: 34249089950     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2974     Document Type: Article

References (58)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2006;56:106-30.
2. Yip I, Heber D, Aronson W. Nutrition and prostate cancer. Urol Clin North Am 1999;26:403-11.
3. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-60.
4. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006;12:3661-97.
5. Dunsmuir WD, Hrouda D, Kirby RS. Malignant changes in the prostate with ageing. Br J Urol 1998; 82:47-58.
6. Shen CA, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2001;14:2410-34.
7. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
8. Albrecht M, Jiang W, Kumi-Diaka J, et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004;7:274-83.
9. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high grade prostate intraepithelial neoplasia, a preliminary report from a one-year proof-of principle study. Cancer Res 2006;66:1234-40.
10. Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG. Resveratrol an extract of red wine inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NFκB B independent mechanism. FASEB J 2005;19:840-1.
11. Choan E, Segal R, Joinker D, et al. A prospective clinical trial of green tea for hormone refractory prostate cancer, an evaluation of the complementary and alternative therapy approach. Urol Oncol 2005;23:108-13.
12. Clinton SK. Tomatoes or lycopene: a role in prostate carcinogenesis. J Nutr 2005;135:2057-9S.
13. Kirsh VA, Mayne ST, Peters U, et al. A prospective study of lycopene and tomato products intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:92-8.
14. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12:4018-26.
15. Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate inhibits HEH-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 2002;62:652-5.
16. Singh AV, Franke AA, Blackburn GL, Zhou JR. Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alteration of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res 2006;66:1851-8.
17. Nahin RL, Straus SE. Research into complementary alternative medicine: problems and potential. Br Med J 2006;322:161-4.
18. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004;3: 349-80.
19. Mori H, Fuchigami M, Inoue N, et al. Principle of the bark Phellodendron amurense to suppress the cellular immune response: effect of Phellodendron on cellular and humoral immune response. Planta Med 1995;61: 45-9.
20. Cuellar MJ, Giner RM, Recio MC, Manez S, Rios JL. Topical anti-inflammatory activity of some Asian medicinal plants used in dermatological disorders. Fitoterapia 2001;72:221-9.
21. Garcia GE, Arevalo N, Bhaskaran S, Gupta A, Kyprianou N, Kumar AP. Akt and CREB mediated prostate cancer cell proliferation inhibition by Nexrutine® a Phellodendron amurense extract. Neoplasia 2006;8: 523-33
22. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in theTRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-5.
23. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in transgenic mouse. Cancer Res 1996;56:4096-102.
24. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64:3334-43.
25. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-5.
26. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H. Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice. Cancer Res 2000;60:5125-33.
27. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006;66:385-92.
28. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary Genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 2005;135: 989-95.
29. Mentor-Marcel R, Lamartiniere CA, Eltoum I-E, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82.
30. Wechter WJ, Leipold DD, Murray DE, et al. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2001;60: 2203-8.
31. Garcia GE, Wisniewski H-G, M Scott Lucia, et al. 2-Methoxyestradiol (2-ME) inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate (TRAMP): role of TNFα-stimulated gene 6 (TSG-6). Clin Cancer Res 2006;12:980-8.
32. 2/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001;31:111-24.
33. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, SlagaTJ. 4-Hydroxymethoxybenzoic acid methyl ester (HMBME): a curcumin derivative targets Akt/NFκB cell survival signaling pathway: potential for prostate cancer management. Neoplasia 2003;5:255-66.
34. Shukla S, MacLennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3K-Akt and NFκB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005;64: 224-39.
35. Malik SN, Brattain M, Ghosh PM, et al. Immunohis-tochemical demonstration of phospho Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-71.
36. Mary B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609.
37. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998;273: 32377-9.
38. Conkright MD, Montminy M. CREB: the unindicted cancer co-conspirator.TrendsCell Biol 2005;15:457-9.
39. Okuno H and Bito H. Creb 1. UCSD-Nature Molecules Pages 2006; doi:10.1038/mp.a000690.01.
40. Okuno H and Bito H. Creb1. Afcs-Nature Molecules Pages 2006; doi:10.1038/mp.a000690.01.
41. Shankar DB, Sakamoto KM. The role of cyclic-AMP binding protein (CREB) in leukemia cell proliferation and acute leukemias. Leuk Lymphoma 2004;45:265-70.
42. Shankar DB, Cheng JC, Kinjo K, et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005;7:351-62.
43. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t (12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993; 4:341-5.
44. Schaefer KL, Brachwitz K, Wai DH, et al. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res 2004;64:3395-405.
45. Olsen RJ, Hinrichs SH. Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins. Oncogene 2001;20:1756-64.
46. Melnikova VO, Mourad-Zeidan AA, Lev DC, Bar-Eli M. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 2006;281:2911-22.
47. Jean D, Harbison M, McConkey DJ, Ronai Z, Bar-Eli M. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem 1998; 273:24884-90.
48. Rosenberg D, Groussin L, Jullian E, Pelemoine K, Bertagna X, Bertherat J. Role of PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. Ann N Y Acad Sci 2002; 968:65-74.
49. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 2005;294:66-70.
50. Tricolli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004; 10:3943-53.
51. Sabbah M, Courilleau D, Mester J, Redcuilh G. Estrogen induction of cyclin D1 promoter involvement of a cAMP response like element. Proc Natl Acad Sci U S A 1999;96:11217-22.
52. White PC, Shore AM, Clement M, et al. Regulation of cyclin D2 and the cyclin D2 promoter by promoter kinase A and CREB in lymphocytes. Oncogene 2006; 25:2170-80.
53. ras mutants and c-Ets2 activate cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-97.
54. Dworet JH, Meinkoth JL. Interference with cAMP response element binding protein (CREB) stimulates apoptosis through aberrant cell cycle progression and checkpoint activation. Mol Endocrinol 2006;20: 1112-20.
55. Saeki K, You A, Suzuki E, Yazaki Y, Takaku F. Aberrant expression of cAMP-response-element-binding protein ('CREB') induces apoptosis. Biochem J 1999; 343:249-55.
56. Debes JD, Comuzzi B, Schmisth LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 2005;65:5965-73.
57. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 2005;65:2303-13.
58. Unni E, Sun S, Nan B, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004;64:7156-8.